ipilimumab
Showing 26 - 50 of 914
Metastatic Castration Sensitive Prostate Cancer Trial in New York (Degarelix, Ipilimumab, Radical Prostatectomy)
Active, not recruiting
- Metastatic Castration Sensitive Prostate Cancer
- Degarelix
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 4, 2022
Pancreatic Cancer, Metastatic Pancreatic Cancer Trial in Boston (Nivolumab, Ipilimumab, Radiation)
Active, not recruiting
- Pancreatic Cancer
- Metastatic Pancreatic Cancer
- Nivolumab
- +2 more
-
Boston, Massachusetts
- +2 more
Sep 7, 2022
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Tumor in the Brain, Metastatic Melanoma Trial in Houston
Recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +3 more
- Ipilimumab
- Pembrolizumab
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Melanoma Trial in New York (Nivolumab, Ipilimumab)
Completed
- Melanoma
- Nivolumab
- Ipilimumab
-
New York, New YorkLaura and Isaac Perlmutter Cancer Center
Aug 11, 2022
Advanced Metastatic Cancer, Advanced Prostate Cancer Trial in United States (Nivolumab Monotherapy, Nivolumab and Ipilimumab and
Active, not recruiting
- Advanced Metastatic Cancer
- Advanced Prostate Cancer
- Nivolumab Monotherapy
- +3 more
-
Los Angeles, California
- +5 more
Dec 16, 2022
Recurrent Glioblastoma Trial in Brussels (Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV,
Not yet recruiting
- Recurrent Glioblastoma
- Neo-adjuvant nivolumab and ipililumab IV + adjuvant nivolumab and ipililumab IV
- +2 more
-
Brussels, BelgiumUZ Brussel
Oct 23, 2023
Locally Advanced or Metastatic Melanoma Trial (CBL0137, Ipilimumab, Nivolumab)
Not yet recruiting
- Locally Advanced or Metastatic Melanoma
- CBL0137
- +2 more
- (no location specified)
Aug 10, 2022
Cancer, Cancer, Lung, Cancer of Lung Trial in Worldwide (UV1 vaccine + leukine, ipilimumab, nivolumab)
Active, not recruiting
- Cancer
- +6 more
- UV1 vaccine + leukine
- +2 more
-
Perth, Australia
- +6 more
Jan 23, 2023
Metastatic Melanoma Trial in Tampa (drug, procedure, biological)
Active, not recruiting
- Metastatic Melanoma
- Ipilimumab
- +6 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Nov 8, 2022
Pancreatic Cancer Trial in Baltimore (Tadalafil, Pembrolizumab, Ipilimumab)
Recruiting
- Pancreatic Cancer
- Tadalafil
- +3 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Aug 23, 2022
Nasopharyngeal Carcinoma Trial in Singapore (Ipilimumab, Nivolumab)
Recruiting
- Nasopharyngeal Carcinoma
- Ipilimumab
- Nivolumab
-
Singapore, SingaporeNational Cancer Center Singapore
Jul 20, 2022
Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in
Active, not recruiting
- Melanoma
- Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
- Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
-
Toulouse, FranceInstitut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022
NSCLC Stage IV, HIV, HBV Trial in Verona (Nivolumab and Ipilimumab)
Not yet recruiting
- NSCLC Stage IV
- +4 more
- Nivolumab and Ipilimumab
-
Verona, Veneto/Verona, ItalyCentro Ricerche Cliniche
Oct 26, 2022
Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma Trial in Boston (Ipilimumab, Laboratory
Active, not recruiting
- Metastatic Leiomyosarcoma
- +2 more
- Ipilimumab
- +2 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
Unresectable or Metastatic Melanoma Trial in Australia, United States (Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4
Terminated
- Unresectable or Metastatic Melanoma
- Ipilimumab
- +3 more
-
New York, New York
- +4 more
Oct 3, 2022
Metastatic Urothelial Carcinoma Trial in Tampa, Boston (Ipilimumab, Nivolumab, Sacituzumab govitecan)
Recruiting
- Metastatic Urothelial Carcinoma
- Ipilimumab
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
Renal Cell Carcinoma Trial in Houston (Ipilimumab, Nivolumab, Ciforadenant)
Not yet recruiting
- Renal Cell Carcinoma
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 11, 2022
Breast Cancer Trial in Los Angeles, Portland (Ipilimumab, Nivolumab, Core Biopsy/Cryoablation)
Recruiting
- Breast Cancer
- Ipilimumab
- +3 more
-
Los Angeles, California
- +2 more
Sep 27, 2022
Immune-related Adverse Event, Diarrhea, Advanced Melanoma Trial in Edmonton (Mesalamine)
Not yet recruiting
- Immune-related Adverse Event
- +3 more
-
Edmonton, Alberta, CanadaCross Cancer Institute
Dec 15, 2022